{"id":194862,"date":"2024-04-25T17:57:17","date_gmt":"2024-04-25T21:57:17","guid":{"rendered":"https:\/\/www.breakthrought1d.org\/normativa\/"},"modified":"2025-07-16T13:35:02","modified_gmt":"2025-07-16T17:35:02","slug":"regulador","status":"publish","type":"page","link":"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/","title":{"rendered":"Normativa"},"content":{"rendered":"\n<div class=\"page-header alignfull wp-block-jdfr-page-header\">\n\t<div class=\"page-header__inner-container\">\n\t\t\n<nav id=\"breadcrumbs\" class=\"site-breadcrumbs alignfull\" aria-label=\"Breadcrumbs\">\n\t<ul class=\"site-breadcrumbs__inner\"><li class=\"breadcrumb-item\"><a href=\"https:\/\/www.breakthrought1d.org\/es\/pagina-de-actualizacion-de-test\/\">Inicio<\/a><\/li><li class=\"site-breadcrumbs__separator\"><?xml version=\"1.0\"?>\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"9.143\" height=\"16\" fill=\"currentColor\" viewBox=\"0 0 9.143 16\" aria-hidden=\"true\"><path d=\"M1.143 16a1.143 1.143 0 0 1-.808-1.951L6.384 8 .335 1.951A1.143 1.143 0 0 1 1.951.335l6.857 6.857a1.143 1.143 0 0 1 0 1.616l-6.857 6.857a1.14 1.14 0 0 1-.808.335\"\/><\/svg>\n<\/li><li class=\"breadcrumb-item\" aria-current=\"page\" tabindex=\"0\" role=\"text\" aria-label=\"P\u00e1gina actual: \"><\/li><\/ul><\/nav>\n\n\t\t<div class=\"page-header__content\">\n\t\t\t<h1 class=\"page-header__title\">Normativa  <\/h1>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group alignfull is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-e50f5278 wp-block-columns-is-layout-flex has-2-columns\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading\" id=\"regulatory-frameworks-that-promote-innovation\">Marcos normativos que fomentan la innovaci\u00f3n<\/h2>\n\n\n\n<p class=\"is-style-large-body wp-block-paragraph\">La pr\u00f3xima generaci\u00f3n de terapias para la diabetes tipo 1 (DT1) ser\u00e1 revolucionaria. Breakthrough T1D trabaja hoy para garantizar que esas terapias tengan un camino claro y razonable desde la investigaci\u00f3n hasta la aprobaci\u00f3n en cualquier parte del mundo.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\"><\/div>\n<\/div>\n\n\n\n<section class=\"wp-block-jdrf-accordion\">\n\n\t<div class=\"wp-block-jdrf-accordion__items\">\n\t\t\n\n<div class=\"wp-block-jdrf-accordion-item\">\n\t<button type=\"button\" class=\"wp-block-jdrf-accordion-item__header accordion-header\">\n\t\t<span id=\"terapias-celulares\" class=\"wp-block-jdrf-accordion-item__title\">\n\t\t\tTerapias celulares\t\t<\/span>\n\n\t\t<span class=\"wp-block-jdrf-accordion-item__icon icon-open\">\n\t\t\t\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"16\" height=\"2\" fill=\"currentColor\" viewbox=\"0 0 16 2\"><path stroke=\"currentColor\" stroke-width=\"1.5\" d=\"M1 .944h14\" \/><\/svg>\n\t\t<\/span>\n\t\t<span class=\"wp-block-jdrf-accordion-item__icon icon-close\">\n\t\t\t\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"16\" height=\"15.999\" viewbox=\"0 0 16 15.999\"><path d=\"M7.314 15.314V8.686H.686A.686.686 0 0 1 0 8a.686.686 0 0 1 .686-.685h6.628V.686A.686.686 0 0 1 8 0a.685.685 0 0 1 .685.685v6.629h6.628A.686.686 0 0 1 16 8a.686.686 0 0 1-.686.686H8.686v6.628A.685.685 0 0 1 8 16a.686.686 0 0 1-.686-.686\" \/><\/svg>\n\t\t<\/span>\n\t<\/button>\n\n\t<div class=\"wp-block-jdrf-accordion-item__content accordion-content\">\n\t\t\n\n<p class=\"wp-block-paragraph\">Breakthrough T1D trabaja para que la v\u00eda reguladora de las terapias celulares para la DT1 sea clara y razonable. Esto incluye adaptar los resultados estudiados a los \u00faltimos avances cient\u00edficos y a la perspectiva de las personas con DT1.<\/p>\n\n\t<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-jdrf-accordion-item\">\n\t<button type=\"button\" class=\"wp-block-jdrf-accordion-item__header accordion-header\">\n\t\t<span id=\"terapias-modificadoras-de-la-condicion\" class=\"wp-block-jdrf-accordion-item__title\">\n\t\t\tTerapias modificadoras de la condici\u00f3n\t\t<\/span>\n\n\t\t<span class=\"wp-block-jdrf-accordion-item__icon icon-open\">\n\t\t\t\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"16\" height=\"2\" fill=\"currentColor\" viewbox=\"0 0 16 2\"><path stroke=\"currentColor\" stroke-width=\"1.5\" d=\"M1 .944h14\" \/><\/svg>\n\t\t<\/span>\n\t\t<span class=\"wp-block-jdrf-accordion-item__icon icon-close\">\n\t\t\t\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"16\" height=\"15.999\" viewbox=\"0 0 16 15.999\"><path d=\"M7.314 15.314V8.686H.686A.686.686 0 0 1 0 8a.686.686 0 0 1 .686-.685h6.628V.686A.686.686 0 0 1 8 0a.685.685 0 0 1 .685.685v6.629h6.628A.686.686 0 0 1 16 8a.686.686 0 0 1-.686.686H8.686v6.628A.685.685 0 0 1 8 16a.686.686 0 0 1-.686-.686\" \/><\/svg>\n\t\t<\/span>\n\t<\/button>\n\n\t<div class=\"wp-block-jdrf-accordion-item__content accordion-content\">\n\t\t\n\n<p class=\"wp-block-paragraph\">Ahora que una terapia modificadora de la condici\u00f3n ha superado el proceso regulador, estamos trabajando para optimizar la v\u00eda para la pr\u00f3xima generaci\u00f3n de terapias. M\u00faltiples terapias adicionales modificadoras de la condici\u00f3n han demostrado su eficacia en los primeros ensayos cl\u00ednicos, y habr\u00e1 m\u00e1s en el futuro. Queremos acelerar el camino hacia la aprobaci\u00f3n de esas terapias para dar a las personas y a sus m\u00e9dicos las mejores opciones de atenci\u00f3n.<\/p>\n\n\t<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-jdrf-accordion-item\">\n\t<button type=\"button\" class=\"wp-block-jdrf-accordion-item__header accordion-header\">\n\t\t<span id=\"dispositivos-para-la-diabetes\" class=\"wp-block-jdrf-accordion-item__title\">\n\t\t\tDispositivos para la diabetes\t\t<\/span>\n\n\t\t<span class=\"wp-block-jdrf-accordion-item__icon icon-open\">\n\t\t\t\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"16\" height=\"2\" fill=\"currentColor\" viewbox=\"0 0 16 2\"><path stroke=\"currentColor\" stroke-width=\"1.5\" d=\"M1 .944h14\" \/><\/svg>\n\t\t<\/span>\n\t\t<span class=\"wp-block-jdrf-accordion-item__icon icon-close\">\n\t\t\t\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"16\" height=\"15.999\" viewbox=\"0 0 16 15.999\"><path d=\"M7.314 15.314V8.686H.686A.686.686 0 0 1 0 8a.686.686 0 0 1 .686-.685h6.628V.686A.686.686 0 0 1 8 0a.685.685 0 0 1 .685.685v6.629h6.628A.686.686 0 0 1 16 8a.686.686 0 0 1-.686.686H8.686v6.628A.685.685 0 0 1 8 16a.686.686 0 0 1-.686-.686\" \/><\/svg>\n\t\t<\/span>\n\t<\/button>\n\n\t<div class=\"wp-block-jdrf-accordion-item__content accordion-content\">\n\t\t\n\n<p class=\"wp-block-paragraph\">Breakthrough T1D est\u00e1 trabajando con las agencias reguladoras para aumentar las opciones y la interoperabilidad de los dispositivos para la diabetes, como los sistemas autom\u00e1ticos de administraci\u00f3n de insulina. Nuestra prioridad es que los componentes de distintos fabricantes funcionen juntos, dando a las personas con DT1 la opci\u00f3n de utilizar los componentes que mejor les funcionen.<\/p>\n\n\t<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-jdrf-accordion-item\">\n\t<button type=\"button\" class=\"wp-block-jdrf-accordion-item__header accordion-header\">\n\t\t<span id=\"control-de-la-glucosa-y-terapias-de-las-complicaciones\" class=\"wp-block-jdrf-accordion-item__title\">\n\t\t\tControl de la glucosa y terapias de las complicaciones\t\t<\/span>\n\n\t\t<span class=\"wp-block-jdrf-accordion-item__icon icon-open\">\n\t\t\t\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"16\" height=\"2\" fill=\"currentColor\" viewbox=\"0 0 16 2\"><path stroke=\"currentColor\" stroke-width=\"1.5\" d=\"M1 .944h14\" \/><\/svg>\n\t\t<\/span>\n\t\t<span class=\"wp-block-jdrf-accordion-item__icon icon-close\">\n\t\t\t\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"16\" height=\"15.999\" viewbox=\"0 0 16 15.999\"><path d=\"M7.314 15.314V8.686H.686A.686.686 0 0 1 0 8a.686.686 0 0 1 .686-.685h6.628V.686A.686.686 0 0 1 8 0a.685.685 0 0 1 .685.685v6.629h6.628A.686.686 0 0 1 16 8a.686.686 0 0 1-.686.686H8.686v6.628A.685.685 0 0 1 8 16a.686.686 0 0 1-.686-.686\" \/><\/svg>\n\t\t<\/span>\n\t<\/button>\n\n\t<div class=\"wp-block-jdrf-accordion-item__content accordion-content\">\n\t\t\n\n<p class=\"wp-block-paragraph\">Breakthrough T1D est\u00e1 trabajando con las agencias reguladoras y otras partes interesadas para integrar nuevos resultados de las terapias de control de la glucosa y las complicaciones de la DT1, incluidos los medidos por los MCG, en el paradigma regulador. Se hace hincapi\u00e9 en garantizar la retroalimentaci\u00f3n de las personas con DT1 sobre los resultados medidos y c\u00f3mo se consideran los beneficios y riesgos de las terapias.<\/p>\n\n\t<\/div>\n<\/div>\n\n\t<\/div>\n<\/section>\n<\/div>\n\n\n\n<div class=\"wp-block-group alignfull has-light-gray-background-color has-background is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-e50f5278 wp-block-columns-is-layout-flex has-2-columns\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:90%\"><div class=\"align wp-block-jdrf-image-quote\">\n\t\t\t<div class=\"wp-block-jdrf-image-quote__media\">\n\t\t\t<figure\n\t\t\t\tclass=\"wp-block-jdrf-image-quote__image\"\n\t\t\t\titemprop=\"image\"\n\t\t\t\titemscope\n\t\t\t\titemtype=\"https:\/\/schema.org\/ImageObject\"\n\t\t\t>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"731\" height=\"1024\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/Campbell-Hutton-Headshot-731x1024.jpg\" class=\"wp-block-jdrf-image-quote__image-attachment\" alt=\"\" style=\"object-position: 52% 13%\" itemprop=\"url\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/Campbell-Hutton-Headshot-731x1024.jpg 731w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/Campbell-Hutton-Headshot-214x300.jpg 214w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/Campbell-Hutton-Headshot-768x1075.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/Campbell-Hutton-Headshot-1097x1536.jpg 1097w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/Campbell-Hutton-Headshot-1463x2048.jpg 1463w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/Campbell-Hutton-Headshot-800x1120.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/Campbell-Hutton-Headshot-1200x1680.jpg 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/Campbell-Hutton-Headshot.jpg 1500w\" sizes=\"auto, (max-width: 731px) 100vw, 731px\" \/>\t\t\t<\/figure>\n\t\t<\/div>\n\t\t\t\t<div class=\"wp-block-jdrf-image-quote__content-wrap\">\n\t\t\t<div class=\"wp-block-jdrf-image-quote__icon\">\n\t\t\t\t\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"22.158\" height=\"15.926\" viewbox=\"0 0 22.158 15.926\" aria-hidden=\"true\"><path d=\"M4.847 15.926a4.34 4.34 0 0 1-3.501-1.616A6.5 6.5 0 0 1 0 10.002q0-6.078 6.155-10l1.846 1.923a6.45 6.45 0 0 0-2.154 4.77 3.44 3.44 0 0 0 .462 1.923 1.42 1.42 0 0 0 1.231.692 1.95 1.95 0 0 0 1.154-.385 4.3 4.3 0 0 1 .846 2.847 3.81 3.81 0 0 1-1.308 3 4.93 4.93 0 0 1-3.385 1.154m12.618 0a4.34 4.34 0 0 1-3.501-1.616 6.5 6.5 0 0 1-1.346-4.308q0-6.078 6.155-10l1.846 1.923a6.45 6.45 0 0 0-2.154 4.77 3.44 3.44 0 0 0 .462 1.923 1.42 1.42 0 0 0 1.231.692 1.95 1.95 0 0 0 1.154-.385 4.3 4.3 0 0 1 .846 2.847 3.81 3.81 0 0 1-1.308 3 4.93 4.93 0 0 1-3.385 1.154\" \/><\/svg>\n\t\t\t<\/div>\n\t\t\t\t\t\t\t<blockquote class=\"wp-block-jdrf-image-quote__quote-text\">Nuestro equipo trabaja cada d\u00eda para reunir a innovadores y reguladores. Esto garantiza que las terapias para la T1D avancen lo m\u00e1s r\u00e1pido -y seguro- posible hacia su aprobaci\u00f3n.&#8221;<\/blockquote>\n\t\t\t\n\t\t\t\t\t\t\t<cite class=\"wp-block-jdrf-image-quote__cite\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"wp-block-jdrf-image-quote__author-name\">Campbell Hutton<\/span>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<span class=\"wp-block-jdrf-image-quote__author-title\">Vicepresidenta de Pol\u00edtica Reguladora y de Salud de Breakthrough T1D<\/span>\n\t\t\t\t\t\t\t\t\t<\/cite>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:10%\"><\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group alignfull has-white-background-color has-background is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-e50f5278 wp-block-columns-is-layout-flex has-2-columns\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<h2 class=\"wp-block-heading has-h-3-font-size\" id=\"a-history-of-success\">Una historia de \u00e9xito<\/h2>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h3 class=\"wp-block-heading has-h-5-font-size\" id=\"the-roadmap-to-automated-insulin-delivery\">La hoja de ruta hacia la administraci\u00f3n automatizada de insulina<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Breakthrough T1D cre\u00f3 el Consorcio del P\u00e1ncreas Artificial en 2005 para hacer realidad estos sistemas. Una parte clave fue reunir a todos, incluidos los organismos gubernamentales, para perseguir esta tecnolog\u00eda que salva vidas y que hoy es la norma de atenci\u00f3n m\u00e9dica.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Breakthrough T1D colabor\u00f3 con la FDA para crear una v\u00eda reglamentaria para la aprobaci\u00f3n de esta tecnolog\u00eda, que condujo a la gu\u00eda de 2012 de la FDA para los sistemas de p\u00e1ncreas artificial.  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Los expertos del sector han afirmado que la participaci\u00f3n de Breakthrough T1D redujo en cinco a\u00f1os el proceso de aprobaci\u00f3n del sistema de p\u00e1ncreas artificial Medtronic 670G en 2016, el primer sistema aprobado.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-1024x683.jpg\" alt=\"Tecnolog\u00eda de administraci\u00f3n automatizada de insulina aprobada exitosamente\" class=\"wp-image-191555\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-1024x683.jpg 1024w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-300x200.jpg 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-768x512.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-1536x1024.jpg 1536w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-2048x1365.jpg 2048w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-800x533.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-1200x800.jpg 1200w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group alignfull has-light-gray-background-color has-background has-gradient is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-e50f5278 wp-block-columns-is-layout-flex has-2-columns\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:90%\"><div class=\"alignright wp-block-jdrf-quote\">\n\t\t\t<blockquote class=\"wp-block-jdrf-quote__blockquote\">\n\t\t\tCreo que [Breakthrough T1D] nos ha tra\u00eddo hasta aqu\u00ed mucho m\u00e1s r\u00e1pido de lo que podr\u00edamos haberlo hecho de otra forma.\u201d\t\t<\/blockquote>\n\t\n\t\t\t<cite class=\"wp-block-jdrf-quote__cite\">\n\t\t\t\t\t\t\t<span class=\"wp-block-jdrf-quote__author-name\">\n\t\t\t\t\tDra. Francine Kaufman\t\t\t\t<\/span>\n\t\t\t\n\t\t\t\t\t\t\t<span class=\"wp-block-jdrf-quote__author-title\">\n\t\t\t\t\tAntiguo Director General de Medtronic, sobre el papel de Breakthrough T1D en el establecimiento de una v\u00eda reglamentaria para los sistemas automatizados de administraci\u00f3n de insulina.\t\t\t\t<\/span>\n\t\t\t\t\t<\/cite>\n\t<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:10%\"><\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group alignfull has-white-color has-navy-background-color has-text-color has-background has-link-color wp-elements-ffc8aa331c4ccb69d88e4a9a1703a1ab is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-e50f5278 wp-block-columns-is-layout-flex has-2-columns\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<h2 class=\"wp-block-heading\" id=\"learn-more-about-our-advocacy\">M\u00e1s informaci\u00f3n sobre nuestra defensa<\/h2>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p class=\"is-style-large-body wp-block-paragraph\">El grupo regulador es s\u00f3lo una parte del equipo de defensa de Breakthrough T1D.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-primary\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.breakthrought1d.org\/es\/defensa\/\">Explore nuestros esfuerzos de defensa<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false,"raw":""},"excerpt":{"rendered":"<p>Marcos normativos que fomentan la innovaci\u00f3n La pr\u00f3xima generaci\u00f3n de terapias para la diabetes tipo 1 (DT1) ser\u00e1 revolucionaria. Breakthrough T1D trabaja hoy para garantizar que esas terapias tengan un camino claro y razonable desde la investigaci\u00f3n hasta la aprobaci\u00f3n en cualquier parte del mundo. Una historia de \u00e9xito La hoja de ruta hacia la [&hellip;]<\/p>\n","protected":false},"author":1222,"featured_media":0,"parent":212305,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"ep_exclude_from_search":false,"publish_on_app_meta":"True","iawp_total_views":18,"footnotes":""},"class_list":["post-194862","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Normativa - Breakthrough T1D<\/title>\n<meta name=\"description\" content=\"Breakthrough T1D gu\u00eda las terapias para la T1D a trav\u00e9s del marco regulador para promover la innovaci\u00f3n y facilitar el camino desde la investigaci\u00f3n hasta la aprobaci\u00f3n\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Normativa - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Breakthrough T1D gu\u00eda las terapias para la T1D a trav\u00e9s del marco regulador para promover la innovaci\u00f3n y facilitar el camino desde la investigaci\u00f3n hasta la aprobaci\u00f3n\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/breakthrought1dHQ\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-16T17:35:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-1024x683.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@breakthrought1d\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/explora-defensa\\\/regulador\\\/\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/explora-defensa\\\/regulador\\\/\",\"name\":\"Normativa - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/explora-defensa\\\/regulador\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/explora-defensa\\\/regulador\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Regulatory_twowomen-1024x683.jpg\",\"datePublished\":\"2024-04-25T21:57:17+00:00\",\"dateModified\":\"2025-07-16T17:35:02+00:00\",\"description\":\"Breakthrough T1D gu\u00eda las terapias para la T1D a trav\u00e9s del marco regulador para promover la innovaci\u00f3n y facilitar el camino desde la investigaci\u00f3n hasta la aprobaci\u00f3n\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/explora-defensa\\\/regulador\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/explora-defensa\\\/regulador\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/explora-defensa\\\/regulador\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Regulatory_twowomen-1024x683.jpg\",\"contentUrl\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Regulatory_twowomen-1024x683.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/explora-defensa\\\/regulador\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/pagina-de-actualizacion-de-test\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Explora nuestros esfuerzos de defensa\",\"item\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/explora-defensa\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Normativa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Improving Lives. Curing Type 1 Diabetes.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/BT1D-favi.png\",\"contentUrl\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/BT1D-favi.png\",\"width\":400,\"height\":400,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/breakthrought1dHQ\",\"https:\\\/\\\/x.com\\\/breakthrought1d\",\"https:\\\/\\\/www.youtube.com\\\/@breakthrought1d\",\"https:\\\/\\\/www.instagram.com\\\/breakthrought1d\\\/\",\"https:\\\/\\\/www.tiktok.com\\\/@breakthrought1dhq\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Normativa - Breakthrough T1D","description":"Breakthrough T1D gu\u00eda las terapias para la T1D a trav\u00e9s del marco regulador para promover la innovaci\u00f3n y facilitar el camino desde la investigaci\u00f3n hasta la aprobaci\u00f3n","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/","og_locale":"es_ES","og_type":"article","og_title":"Normativa - Breakthrough T1D","og_description":"Breakthrough T1D gu\u00eda las terapias para la T1D a trav\u00e9s del marco regulador para promover la innovaci\u00f3n y facilitar el camino desde la investigaci\u00f3n hasta la aprobaci\u00f3n","og_url":"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/","og_site_name":"Breakthrough T1D","article_publisher":"https:\/\/www.facebook.com\/breakthrought1dHQ","article_modified_time":"2025-07-16T17:35:02+00:00","og_image":[{"url":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-1024x683.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@breakthrought1d","twitter_misc":{"Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/","url":"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/","name":"Normativa - Breakthrough T1D","isPartOf":{"@id":"https:\/\/www.breakthrought1d.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/#primaryimage"},"image":{"@id":"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/#primaryimage"},"thumbnailUrl":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-1024x683.jpg","datePublished":"2024-04-25T21:57:17+00:00","dateModified":"2025-07-16T17:35:02+00:00","description":"Breakthrough T1D gu\u00eda las terapias para la T1D a trav\u00e9s del marco regulador para promover la innovaci\u00f3n y facilitar el camino desde la investigaci\u00f3n hasta la aprobaci\u00f3n","breadcrumb":{"@id":"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/#primaryimage","url":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-1024x683.jpg","contentUrl":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/04\/Regulatory_twowomen-1024x683.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/regulador\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.breakthrought1d.org\/es\/pagina-de-actualizacion-de-test\/"},{"@type":"ListItem","position":2,"name":"Explora nuestros esfuerzos de defensa","item":"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/"},{"@type":"ListItem","position":3,"name":"Normativa"}]},{"@type":"WebSite","@id":"https:\/\/www.breakthrought1d.org\/es\/#website","url":"https:\/\/www.breakthrought1d.org\/es\/","name":"Breakthrough T1D","description":"Improving Lives. Curing Type 1 Diabetes.","publisher":{"@id":"https:\/\/www.breakthrought1d.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.breakthrought1d.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.breakthrought1d.org\/es\/#organization","name":"Breakthrough T1D","url":"https:\/\/www.breakthrought1d.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.breakthrought1d.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","contentUrl":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","width":400,"height":400,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/www.breakthrought1d.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/breakthrought1dHQ","https:\/\/x.com\/breakthrought1d","https:\/\/www.youtube.com\/@breakthrought1d","https:\/\/www.instagram.com\/breakthrought1d\/","https:\/\/www.tiktok.com\/@breakthrought1dhq"]}]}},"_links":{"self":[{"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/pages\/194862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/users\/1222"}],"replies":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/comments?post=194862"}],"version-history":[{"count":0,"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/pages\/194862\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/pages\/212305"}],"wp:attachment":[{"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/media?parent=194862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}